Introduction {#s0001}
============

As neurons age, their dependence on mechanisms of protein clearance for survival increases even as the competence of these proteolytic systems progressively declines. In adult onset neurodegenerative diseases such as Alzheimer disease (AD), amyotrophic lateral sclerosis, and Parkinson disease, the responsible pathogenic protein accumulates only late in life, reflecting an emergence of aging- and disease-related deficits in eliminating damaged proteins.[@cit0001] Autophagy, the principal lysosomal pathway for turning over intracellular constituents, is closely linked to the mechanisms underlying cellular aging and longevity[@cit0004] and is upregulated during cellular stress.[@cit0007] Several subtypes of autophagy are known, which are distinguished by how substrates are delivered to lysosomes.[@cit0008] The major one of these subtypes, macroautophagy, hereafter referred to as autophagy, supports both the constitutive and selective turnover of a broad range of cell constituents and is also the only mechanism available to neurons for eliminating damaged organelles and large protein aggregates.[@cit0009] Acting in concert with the BECN1-PIK3C3/VPS34 complex and several ubiquitin-ligase complexes,[@cit0010] ULK1 initiates the formation of an elongating double-membrane structure that surrounds the substrate(s) and closes to form a vacuole, termed the autophagosome.[@cit0012] Sequestration of substrates within an autophagosome involves their engagement with the phagophore membrane via LC3 proteins and other autophagy receptors such as SQSTM1/p62,[@cit0013] which facilitate selective cargo recruitment and are themselves ultimately degraded by autophagy.

Autophagosome clearance is initiated upon fusion with lysosomes and/or late endosomes, which introduce into the resulting autolysosome the dozens of lysosomal acidic hydrolases and the acidification machinery necessary for enzyme activation and substrate digestion.[@cit0001] The release of amino acids from autolysosomes and other factors maintain MTOR in its active state to inhibit autophagy induction in a feedback manner.[@cit0016] Under conditions of nutrient deprivation or cellular/lysosomal stress, however, MTOR may become inhibited, leading to nuclear translocation of MiTF/TFE family proteins that positively regulate genes controlling lysosomal biogenesis and some aspects of autophagosome formation.[@cit0019] These include members of the MiTF/TFE transcription factor family such as TFE3 (transcription factor binding to IGHM enhancer 3) and TFEB (transcription factor EB), which bind to a specific E-box (the *"CLEAR sequence"*) on the promoter of a large group of autophagic-lysosomal genes to promote their expression.[@cit0020] Additional transcription factors from the FOXO (forkhead box) family, including FOXO1 and FOXO3, positively regulate smaller subsets of genes supporting autophagy in response to stress-responsive protein kinases such as AKT.[@cit0023]

Autophagy flux is markedly impaired in AD and AD models although information on the stage(s) of autophagy impaired and the molecular basis for deficits, especially in the authentic disease in humans, is incomplete and conflicting.[@cit0024] The widespread appearance of dystrophic neurites filled mainly with autophagic vacuoles containing incompletely digested cellular constituents is a hallmark neuropathological feature of AD,[@cit0026] along with the classical intraneuronal aggregates of MAPT/tau[@cit0029] and extracellular deposits of β-amyloid.[@cit0030] The storage of undigested substrates in AD brain, which is more extensive than in other adult-onset neurodegenerative disorders, reflects a major defect in lysosomal clearance mechanisms.[@cit0026] That these lysosomal system deficits are key pathogenic factors in AD is strongly suggested by growing evidence that selectively restoring lysosomal proteolytic function in mouse AD models ameliorates diverse pathological, synaptic, and cognitive deficits.[@cit0031] Although lysosomal function is evidently deficient in AD models,[@cit0025] reports of additional alterations of earlier steps of autophagy (e.g. autophagy induction, autophagosome formation) have been conflicting,[@cit0034] reflecting, in many cases, limited analysis of human samples and inferences made from a single or relatively few indices of autophagic function as well as the use of brain tissue composed of diverse cell types varying in their responses to disease.[@cit0038] Here, we assessed all of the major steps of the autophagy pathway to evaluate the initiation as well as subsequent autophagy flux and the implications for the development of AD pathology.

In the present study, we used a unique approach involving the evaluation of autophagy alterations specifically within the vulnerable CA1 hippocampal neuronal population of AD brains by determining the expression profile of 44 selected autophagy-related genes in relation to 534 other degenerative disease-related genes comprising a custom-designed microarray platform.[@cit0038] Expression changes in autophagy-related genes were interpreted in relation to morphological alterations of autophagy-related autophagic organelles in CA1 neurons combined with analyses of mRNA and levels, subcellular distributions, and activities of autophagy-related proteins in the hippocampus, which collectively reflect the functional activity of autophagy induction and autophagosome formation as well as the biogenesis and degradative capability of lysosomes. We also analyzed the changes in neuron-specific expression of major transcriptional regulators of autophagy and lysosomal biogenesis in AD brain. Our analysis reveals that autophagy is upregulated early and progressively in AD, despite an evolving impairment in the ability to clear autophagic substrates. This combination of pathological events provides a plausible basis for the well-described massive accumulations of substrate-laden autolysosomes within dystrophic neurites that are a hallmark of AD neuropathology.[@cit0041]

Results {#s0002}
=======

Autophagosome formation is upregulated in CA1 neurons in AD brain {#s0002-0001}
-----------------------------------------------------------------

To obviate limitations of autophagy analyses at the regional brain tissue level, which includes the differential expression patterns of heterogeneous cell types, we re-analyzed a previously published microarray made on single case populations of CA1 pyramidal neurons microaspirated by laser capture microdissection (LCM), focusing on the mRNA expression of 44 autophagy-related genes (out of 578 total genes on the custom-designed array platform).[@cit0040] The 44 genes selected as autophagy-related were classified by curating gene ontology databases using the most recent biological evidence supporting a relevant function in autophagy ([Fig. 1A](#f0001){ref-type="fig"}; see Materials and Methods). Considering Br. III/IV (n = 14) and V/VI (n = 15) together ([Table 1](#t0001){ref-type="table"}), we observed that a disproportionately high percentage of the genes related to autophagy (34%, 15/44) were significantly upregulated relative to controls (n = 10) whereas only 2% of this group were downregulated (1/44) ([Fig. 1A, B](#f0001){ref-type="fig"}). By comparison, considering all 578 genes on the microarray, only 6% (38/578) were significantly upregulated while a relatively high percentage (15%, 85/578) were downregulated ([Fig. 1C](#f0001){ref-type="fig"}). Analysis of the Gene Ontology (GO) terms for highly expressed gene groups confirmed that "Autophagy" was the most highly represented biological process in our gene array ([Fig. 1D](#f0001){ref-type="fig"}). Notably, the majority of the upregulated autophagy genes were significantly altered in both Br. III/IV and V/VI cases ([Fig. 1A](#f0001){ref-type="fig"}), suggesting that autophagy responses in these neurons arise early and are then maintained during the progression of the disease. Upregulated autophagy genes included those involved in induction signaling (*AKT1* and *MAPK3*), autophagosome formation (*ATG3, ATG5, ATG12*, and *ATG8* orthologs *GABARAP* and *MAP1LC3A*), autophagosome-lysosome trafficking/fusion (*RAB7A*[@cit0042] and *RAB24*), lysosomal biogenesis/proteolysis (*CLCN7, LAMP1* and *CTSD*) and other RAB proteins involved in autophagy (*RAB4A*[@cit0043] and *RAB5A*[@cit0038]). We performed additional qPCR measurements in the CA1 sector of the hippocampus on an independent cohort of controls, Br. III and Br. V cases shown in [Table 3](#t0003){ref-type="table"} (n = 9, 10, 10 respectively) that validated these microarray findings. As shown in [Fig. 1E](#f0001){ref-type="fig"}, 7 of 8 genes that were measured by qPCR analyses (the first 8 genes represented) for comparison to microarray analysis match in terms of the direction of change or absence of change, although qPCR analyses reflect expression from a mixed cell population in hippocampal tissue. The strong upregulation in AD brain of a particular set of *ATG* genes from our array (*ATG3, ATG5*, and A*TG12*) and 2 additional genes, *ULK1* and *PIK3C3/VPS34* measured by qPCR suggested the possible activation of FOXO transcription factors, which regulate a select group of autophagic genes,[@cit0045] including the 5 from our study. Consistent with this possibility, *FOXO1* was significantly upregulated by qPCR assessment (p ≤ 0.005) whereas *FOXO3* expression was unchanged ([Fig. 1E](#f0001){ref-type="fig"}). Figure 1.Changes in expression of autophagy-related genes in hippocampal CA1 pyramidal neurons. (A) Autophagy-related genes showing differential regulation in CA1 neurons via custom-designed microarray analysis of 578 genes. Significantly (p ≤ 0.05) altered in both Br. III/IV and Br. V/VI shown in dark gray; others significantly altered in Br. V/VI only shown in black, no change in gray. (B) Pie chart indicating proportions of significantly upregulated and downregulated autophagy genes on the array platform. (C) Pie chart illustrating a relative paucity of genes upregulated in all 578 transcripts contrasting with the higher proportion that are downregulated. (D) GO analysis of all highly expressed genes in Br. III/IV and Br. V/VI when compared to control group. Autophagy, the most represented term, is highlighted in darker blue. p value cut off 0.05. (E) qPCR validation of selected autophagy/lysosomal genes assayed in the CA1 sector of the hippocampus. Statistical significance is denoted by asterisks with p-values shown determined by one-way ANOVA or for 2 column analysis by Student *t* test. \*p ≤ 0.05; \*\*p ≤ 0.01. Table 1.Demographics of brain samples utilized in tissue microarray analysis from the Rush University Religious Orders Study (RROS) and the University of Pennsylvania Center for Neurodegenerative Disease Research (CNDR).Sample numberBraak stageBrain bankPMI (h)Age at deathApoERace/SexCtr. 1IRROS2.385.2E3/3WFCtr. 2IIRROS5.276.8E3/3WMCtr. 3IIRROS7.572.5E3/4WFCtr. 4IRROS8.581.9E3/3WFCtr. 5IRROS12.581.2E3/3WMCtr. 6IRROS567.4E2/3WMCtr. 7NDRROS487NDNDCtr. 8ICNDR881E3/3BFCtr. 90CNDR5.567E3/3WFCtr. 10ICNDR1564NDND**Avg/Tot**  **7.4 + 3.976.4 + 8.2** **5F/3M/2ND**Br. III/IV 1IIIRROS1192.8E3/3WMBr. III/ IV 2IIIRROS489.6E2/3WMBr. III/ IV 3IIIRROS3.688.7E3/3WFBr. III/ IV 4IIIRROS2.892.3E3/3WFBr. III/ IV 5IVRROS397.5E2,3WFBr. III/IV 6IVRROS13.489.2E3/4WMBr. III/IV 7IVRROS3.682.5E3/3WFBr. III/IV 8IVRROS4.880.5E3/3WFBr. III/IV 9IIIRROS4.382.1E3/3WMBr. III/IV 10IVRROS881E4/4WFBr. III/IV 11IVRROS1381.5E3/3WFBr. III/IV 12IVRROS1684.1E3/3WMBr. III/IV 13IVRROS683.5E3/4WFBr. III/IV 14IIICNDR789E3/3BF**Avg/Tot**  **7.2 + 4.486.7 + 5.3** **9F/5M**Br. V/VI 1VRROS687NDMBr. V/VI 2VRROS580NDMBr. V/VI 3VRROS8.581NDFBr. V/VI 4VRROS10.784.2E3/3WFBr. V/VI 5VRROS3.584.8E3/4WMBr. V/VI 6VRROS2.282.7E4/4WMBr. V/VI 7VRROS4.580.1E3/4WMBr. V/VI 8VRROS3.192.8E3/3WFBr. V/VI 9VRROS494.1E2/4WFBr. V/VI 10VICNDR669NDWFBr. V/VI 11VICNDR1775NDWMBr, V/VI 12VICNDR862E2/3WMBr. V/VI 13IVCNDR1291NDWFBr. V/VI 14VICNDR786NDBFBr. V/VI 15VICNDR780NDWF**Avg/Tot**  **7.0 + 3.982.0 + 8.6** **8F/7M**[^2]

Additional support for the upregulation of autophagy in AD brain was provided by quantitative western blot analyses of hippocampal homogenates prepared from tissue used in qPCR analyses ([Table 3](#t0003){ref-type="table"}). Results revealed no significant change of ULK1 levels, but elevated levels of PIK3C3/VPS34 (p ≤ 0.01), a component of the BECN1-PIK3C3/VPS34 complex that is positively regulated by ULK1[@cit0001] ([Fig. 2A, B](#f0002){ref-type="fig"}) in Br. V. Increased autophagosome formation in AD cases was also supported by elevated levels of the autophagic marker LC3B-II and LC3B-I in hippocampal total homogenate of Br. V samples (p ≤ 0.01) ([Fig. 2A, B](#f0002){ref-type="fig"}) and a marked increase in the total area/cell and in number of LC3-positive puncta in AD CA1 neurons ([Fig. 5A, C, D](#f0005){ref-type="fig"}) detectable already at Br. III. We also detected an increase of FOXO1 levels at Br. V ([Fig. 2C, D](#f0002){ref-type="fig"}). Figure 2.Evaluation of autophagy induction in AD. (A) Western blot analysis of indices of autophagic induction and autophagosome formation for ULK1, BECN1, PIK3C3/VPS34, ATG7, LC3, and SQSTM1/p62 and degradative products in AD hippocampus. (B) Histogram illustrating quantification of the findings in (A). (C--D) Western blot analysis of FOXO1 and FOXO3 levels in AD and control hippocampal tissue. Samples analyzed from patients as Control (n = 9), from AD Br. III (n = 10) and from AD Br. V (n = 10). Significance determined by one-way ANOVA with post-hoc Dunnett\'s Comparison to Control test. \*p ≤ 0.05; \*\*p ≤ 0.01. Western blots cropped as shown for purposes of clarity.

Lysosomal biogenesis is mediated by TFE3 in CA1 neurons in AD brain {#s0002-0002}
-------------------------------------------------------------------

Upregulated lysosomal biogenesis in neurons in AD has previously been suggested by lysosomal morphometry[@cit0046] and lysosomal protease CTSD (cathepsin D) expression patterns[@cit0047] in affected neuronal populations of AD brain along with upregulation of *CTSD* gene and protein expression in neurofibrillary tangle-bearing CA1 pyramidal neurons.[@cit0048] This earlier conclusion was strongly supported by microarray data obtained from hippocampal CA1 pyramidal neurons showing upregulated mRNA expression for 3 genes containing the CLEAR site in their promoter sequence, *LAMP1, CLCN7*, and *CTSD*, which was confirmed in the hippocampus by qPCR analysis of *CTSD* and *LAMP1* ([Fig. 1A, E](#f0001){ref-type="fig"}). LAMP2, which is not a CLEAR family member,[@cit0022] was not altered at the mRNA or protein levels. Consistent with mRNA findings, levels of CTSD and CTSB protein were also significantly elevated in hippocampus (p≤0.01, [Fig. 3A, B](#f0003){ref-type="fig"}) although levels of LAMP1 protein were not significantly increased. The discrepancy between the mRNA and protein levels of LAMP1 may be attributed to other levels of regulation between transcripts and protein products.[@cit0049] Of the 44 genes related to autophagy analyzed by microarray, we also found 3 other genes containing the CLEAR site sequence (*RAB5A, RAB7A* and *GABARAP*) that were upregulated at the mRNA level. In light of these data, we next investigated in CA1 neurons the state of activation of the MiTF/TFE family of transcription factors known to regulate lysosomal biogenesis and CLEAR family proteins. To evaluate further roles for MiTF/TFE family members in autophagy upregulation in AD, we first measured *TFEB* and *TFE3* mRNA levels by qPCR in a CA1 neuron population microdissected from hippocampus ([Table 2](#t0002){ref-type="table"}, Ctr. Vs. Br. V, n = 5, 10 respectively) and also in whole hippocampal extracts from AD and control brains ([Table 3](#t0003){ref-type="table"}) shown in [Fig. 4A, B](#f0004){ref-type="fig"}. Surprisingly, *TFE3* mRNA levels were higher than those of *TFEB* in hippocampus, as indicated by an amplification plot showing an ≈1 cycle difference in CT values ([Fig. 4C](#f0004){ref-type="fig"}). Moreover, *TFE3* mRNA expression was greater in Br. V CA1 neurons (p ≤ 0.0001; [Fig. 4A](#f0004){ref-type="fig"}) and also in whole AD hippocampal extracts (p ≤ 0.05; [Fig. 4B](#f0004){ref-type="fig"}) compared to controls. Figure 3.Analysis of lysosomal constituents in AD hippocampus. (A) Western blot analysis of structural and enzymatic constituents of lysosomes with quantification shown in (B). Samples analyzed from control patients (n = 9), from AD Br. III (n = 10) and from AD Br. V (n = 10). Significance determined by one-way ANOVA, with post-hoc Dunnett\'s Comparison to Control test. \*\*p ≤ 0.01. Western blots cropped as shown for purposes of clarity. Figure 4.Analysis of TFE3 and TFEB transcription factors in hippocampal CA1 pyramidal neurons and glia. (A) qPCR analysis of CA1 neurons for *TFE3* and *TFEB*. (B) qPCR for both *TFEB* and *TFE3* in hippocampal total RNA. (C) Amplification plots for *TFE3* (red) and *TFEB* (green) showing a 1.2 cycle difference equivalent to a greater than 10-fold higher level of *TFE3* mRNA in hippocampal tissue. (D--E) Western blot analysis for TFE3 and TFEB in hippocampal tissue and relative quantification showing higher levels of TFE3. Samples analyzed from control patients (n = 9), from AD Br. III (n = 10) and from AD Br. V (n = 10). (F) Immunocytochemical localization of TFE3 in the hippocampal CA1 region. Cells immunostained for TFE3 and counterstained with Nissl. Black arrowheads indicate translocation of TFE3 in neuronal nuclei; blue arrowheads point to negative TFE3 nuclear staining. Scale bar: 10 μm. (G) Quantification of TFE3 nuclear translocation in glia and neurons. (H) Fluorescent immunolocalization of TFEB (yellow arrowheads for neuronal, blue for glia) with Nissl staining shows neuronal or glial nuclei and with decreasing Nissl staining on nuclear translocation in hippocampal CA1 region. Scale bar: 10 μm. (I) Quantification of TFEB nuclear translocation in glia and neurons. A minimum of 50 fields were quantified per condition. Statistical significance denoted by asterisks with p-values shown determined by one-way ANOVA, with post-hoc Dunnett\'s Comparison to Control test, or for 2 columns analysis by Student *t* test. \*p ≤ 0.05; \*\*p ≤ 0.01; \*\*\*p ≤ 0.001; \*\*\*\*p ≤ 0.0001. Figure 5.Double-immunofluorescent labeling of the CA1 region with LC3 and CTSD. (A) Immunofluorescent staining for LC3 (green channel) and CTSD (red) in CA1 hippocampal neurons from Control, Br. III and V. Scale bar: 20 μm. (B) Pearson\'s correlation coefficient of colocalization of CTSD with LC3 in hippocampal CA1 neurons. A minimum of 100 neurons were quantified per condition. (C--D) Characterization of vesicles in Control, Br. III and V CA1 neurons, identified as autophagosome (AP, LC3-positive, CTSD-negative vesicles), autolysosome (AL, LC3- and CTSD-positive vesicles) and lysosome (Ly, LC3-negative, CTSD-positive vesicles). Depicted is the total number and area covered per cell in (C) and (D) respectively. (E) Size distribution of autolysosomes in Control, Br. III and V CA1 neurons. Statistical significance denoted by asterisks with p-values shown determined by one-way ANOVA, with post-hoc Dunnett\'s Comparison to Control test for grouped analyses, and 2-way ANOVA for size distribution analyses. \*p ≤ 0.05; \*\*p ≤ 0.01; \*\*\*p ≤ 0.001**.** Table 2.Emory Alzheimer\'s Disease Resource Center (ADRC) demographics of single cell qPCR analysis of transcriptional activators.Sample No.Case numberBraak stagePMI (h)Age at onsetAge at deathDurationApoERace/SexCtr. 1OS99-08I3 74 E3/3WFCtr. 2OS03-380II12 61 E3/4BMCtr. 3OS03-390II7 74 E3/3WFCtr. 4E10-142II5.5 94 E3/3WMCtr. 5E14-06I12.5 56  WM**AVG/Tot**. **8.0 + 4.1** **71.8 + 14.7**  **3M/3F**Br. V 1OS00-11V449556E3/3WMBr. V 2E05-67V11.5526210E3/4WMBr. V 3E07-36V22 91 E3/3WMBr. V 4E09-65V1077858E4/4WFBr. V 5E10-56V15.576826E4/4BFBr. V 6OS01-10V879878E3/4WFBr. V 7E04-179V20779114E3/4WFBr. V 8E13-134V17.575794 WFBr. V 9E08-97V19 78 E3/4WF**AVG/Tot**  **14.2 + 6.1** **78.9 + 12.6**  **3M/6F**[^3]

In accord with mRNA levels, TFE3 protein levels were also increased in AD brain at both Braak stages (p ≤ 0.01; [Fig. 4D, E](#f0004){ref-type="fig"}). Most importantly, TFE3 immunocytochemistry (ICC) revealed that a significantly higher percentage of CA1 neurons exhibited translocation of TFE3 immunoreactivity from the cytoplasm to the nucleus ([Fig. 4F, G](#f0004){ref-type="fig"}), indicating activation of TFE3. Notably, TFEB mRNA levels in microdissected CA1 neurons were unchanged in AD, whereas levels were significantly increased in Braak stage V AD hippocampal tissue (p ≤ 0.05; [Fig. 4A, B](#f0004){ref-type="fig"}). The AD-related increase in hippocampus, but not in CA1 neurons, raised the possibility that the elevated *TFEB* expression was in glial cells. This observation is consistent with our preliminary evidence that *TFEB* is more highly expressed in glia than in neurons (unpublished data). Accordingly, TFEB protein levels did not differ in total extracts of hippocampus between AD and controls ([Fig. 4D, E](#f0004){ref-type="fig"}). However, fluorescence immunolabeling of TFEB in a semi-quantitative analysis of signal intensity confirmed that the frequency of glial cells with positive nuclear TFEB labeling was significantly higher in AD Braak V stage hippocampus ([Fig. 4H, I](#f0004){ref-type="fig"}). In contrast to glia, only a very small percentage of CA1 neurons exhibited nuclear translocation of TFEB, albeit at a significantly higher frequency in mild/moderate AD cases than in controls ([Fig. 4I](#f0004){ref-type="fig"}). Taken together, these data indicate a more prominent role for TFE3 in promoting lysosomal biogenesis and autophagy upregulation in CA1 neurons during AD pathogenesis and point to a relatively more important role for TFEB in glia of CA1 hippocampus.

Clearance of autophagic substrates by lysosomes is defective in CA1 neurons in AD {#s0002-0003}
---------------------------------------------------------------------------------

Despite evidence that lysosomal biogenesis is more activated in AD brain, including our earlier studies,[@cit0046] additional observations indicated that lysosomal degradative efficiency is impaired. To evaluate lysosomal function, we assessed LC3 clearance specifically in CA1 pyramidal cells using double-immunofluorescence labeling analysis with antibodies to the autophagosome marker LC3 and the lysosomal hydrolase CTSD ([Fig. 5A](#f0005){ref-type="fig"}). Qualitatively, the presence of LC3 in many CTSD-positive neurons was readily apparent in Br. III CA1 hippocampus and quantitative image analysis confirmed a significant increase of Pearson\'s correlation coefficient for LC3-CTSD colocalization, with further increase to nearly 4-fold in Br. V CA1 neurons compared to controls (p ≤ 0.001; [Fig. 5B](#f0005){ref-type="fig"}). Most LC3 signal colocalized within CTSD-positive vesicles; in fact, the relative area and number of LC3-positive puncta containing no CTSD signal (i.e. autophagosomes) was decreased in CA1 neurons in AD Br. III and was not changed in AD Br. V, suggesting that the formation of autolysosomes (ALs), derived by the fusion of an autophagosome (AP) and lysosome (CTSD-positive vesicles negative for LC3), within the neuronal perikarya, was not compromised in AD. Interestingly, at Br. III stage, we observed a significant increase of area occupied by ALs associated with a decrease of area and number of APs and lysosomes ([Fig. 5C, D](#f0005){ref-type="fig"}), as a sign of an early upregulation of autophagy and possibly of more efficient AP-lysosome fusion. With the progression of the disease, there was an accumulation of ALs indicated by a significantly increased number and total area of these structures (p ≤ 0.001; [Fig. 5C, D](#f0005){ref-type="fig"}), reinforcing the notion of progressively impaired turnover of LC3 in CA1 neurons at late stages of AD. In further support of progressively dysfunctional autophagic clearance, size analysis revealed significantly increased numbers of ALs between 0.51--1.41 μm^2^ and 1.41--7.0 μm^2^ (p ≤ 0.01 and p ≤ 0.05, respectively, [Fig. 5E](#f0005){ref-type="fig"}) at Br. III stage while at Br. V, all sizes categories of ALs were abnormally enlarged, presumably with accumulated substrate ([Fig. 5E](#f0005){ref-type="fig"}). Consistent with these data, immunoblots revealed increased levels of LC3-II and a second autophagic substrate SQSTM1/p62 and its intermediate breakdown products (p ≤ 0.05-0.001; [Fig. 2C, D](#f0002){ref-type="fig"}), at Br. V. Collectively, these findings indicate that autolysosomal proteolytic function becomes progressively impaired in CA1 neurons in AD.

Autophagy deficits in AD can be interrogated further by analysis of the prominent neuritic dystrophy characteristic of this disease.[@cit0026] In the hippocampal CA1 region of Br. V samples, immunostaining for LC3 and CTSD revealed dystrophic neurites in the neuropil, which were strongly positive for both antibodies ([Fig. 6A](#f0006){ref-type="fig"}). Dystrophic neurites are more numerous adjacent to senile plaques that are identified as large amorphous granular deposits that are weakly positive for CTSD, consistent with earlier established neuropathological patterns.[@cit0050] Examination of z-stack images of a typical dystrophic swelling ([Fig. 6B](#f0006){ref-type="fig"}) revealed abundant autophagic vesicles of varying subtypes positive for LC3 co-existing with ones positive for CTSD, consistent with ultrastructural analyses showing that dystrophic neurites in AD brain are filled nearly completely with undigested autophagic vacuoles rather than with mixtures of different organelles.[@cit0026] Autolysosomes containing LC3 (CTSD- and LC3-positive) are abundant, as in the perikarya. Large LC3-positive, CTSD-negative autophagosomes, however, are also common raising a possibility that, in axons, fusion between these 2 compartments may be less efficient; however, the numbers of lysosomes in axons is limited and the abundance of APs in neurites is more likely due to limited availability of neurite lysosomes rather than inefficient AP-lysosome fusion. The pattern in dystrophic neurites reinforces the conclusion that autolysosomal proteolysis is impeded, which has been previously shown to selectively slow the retrograde transport of autophagic vacuoles that can promote dystrophic swellings.[@cit0051] Figure 6.Neuritic dystrophy adjacent to senile plaques in the CA1 region in AD brains. (A) The image of AD Br. V hippocampal CA1 depicts a population of putative dystrophic neurites (white arrowheads in the merged image) surrounding a weakly CTSD-positive senile plaque (P). (B) Z-stack images of consecutive optical slices through the single profile indicated by the box in (A) confirms the typical appearance of a dystrophic neurite, which is shown to contain mainly autophagic vacuoles including LC3-positive AP (green), LC3- and CTSD-positive AL, (yellow-orange vesicles) and less frequent CTSD-positive-only lysosomes (red). Scale bar: 10 μm.

Since neuronal cell loss is widely reported in AD[@cit0052] and may influence analyses at a tissue level, we also performed quantitative immunoblot analyses of the CA1 sector of the hippocampus, which revealed a 24% reduction of neuron-specific TUBB3 (p ≤ 0.05) in Braak stage V hippocampus, indicative of a mild-to-moderate loss of neurons as expected ([Fig. 7](#f0007){ref-type="fig"}). Similar analyses of GFAP (glial fibrillary acidic protein) indicated a significant 85% increase in GFAP (p ≤ 0.01; [Fig. 7](#f0007){ref-type="fig"}), consistent with the expected reactive astrogliosis. These data highlight the importance of the cell population-specific analyses in this study, which are substantially less influenced by these changes in cellular composition in the AD hippocampus. Figure 7.Expression of cell-type markers in AD hippocampus shows alterations in neuronal and glial content. (A) Representative western blots illustrating neuronal ΤUBB3 and glial GFAP markers in AD and control hippocampus. (B) Relative quantification of markers in hippocampus indicates downregulation of neuronal-specific TUBB3 and upregulation of GFAP, consistent with neuronal cell loss and concomitant astrogliosis. Statistical significance denoted by asterisks with p-values shown determined by one-way ANOVA, Dunnett\'s test. \*p ≤ 0.05; \*\*p ≤ 0.01. Western blots cropped as shown for purposes of clarity.

Discussion {#s0003}
==========

Our study is the first analysis of multiple stages of autophagy specifically in a single vulnerable population of neurons during the progression of AD. The cell-specific approaches used were designed to overcome notorious limitations of molecular neuropathological analysis in brain tissue, where cell populations are heterogeneous and responses of individual neuronal and/or non-neuronal populations, including differential cell losses, are admixed.[@cit0040] By assessing autophagy broadly, we could obtain a relatively full picture of the variables contributing to the robust autophagy pathology in AD brain.

We establish that autophagy induction and autophagosome formation in CA1 pyramidal neurons are competent and, in fact, are upregulated at the transcriptional level early in AD development and remain upregulated even as the clearance of autophagic substrates by lysosomes becomes progressively impaired. An activation of neuronal autophagy in AD is supported by independent lines of evidence established in microaspirated CA1 neurons and regional hippocampal dissections, including: (a) increase in the total area/cell and in number of LC3-positive puncta, (b) increased expression of key components involved in autophagosome formation; and (c) activation of TFE3 and TFEB transcription factors regulating lysosomal biogenesis and additional genes that support autophagy.[@cit0020] Notably, analysis of significantly altered transcripts by DAVID software[@cit0055] identified the autophagy pathway as the most broadly upregulated gene family among the gene ontology groups represented on our microarray. Most other gene ontology groups altered in CA1 neurons were downregulated, notably transcripts encoding NTFs/neurotrophins and neurotrophin receptors, synaptic-related proteins, and components related to glutamatergic neurotransmission.[@cit0038] Many of the autophagy subgroup of genes are targets of the MiTF/TFE and FOXO families of transcription factors. MiTF/TFE family members are activated upon induction of autophagy[@cit0056] or prolonged mitochondrial stress[@cit0058] in order to sustain both autophagosome formation and clearance by lysosomes (lysosome biogenesis). Our results establish TFE3 as the pre-eminent MiTF/TFE family member in hippocampal neurons. By contrast, TFEB, often considered the most relevant master transcriptional regulator of autophagy and lysosome function,[@cit0020] showed greater nuclear translocation in glial cells, perhaps to support reactive gliosis and the scavenging of dying neuronal processes and/or aggregated proteins. The changing cellular composition observed in Br. V hippocampus, including astrogliosis and moderate loss of neuron-specific markers underscores the importance of our cell-specific analytical approaches. Autophagy assessment in tissue is complicated by these changes as well as by evidence that some autophagy-related components are differentially expressed in neurons and glia, and responses of these different cell types to disease and pathology are likely to differ.

Because autophagosome clearance is impaired in AD,[@cit0024] it has previously been difficult to determine whether increased induction/autophagosome formation also contributes to the massive buildup of autophagy substrates in AD brain. Earlier investigations of autophagy induction in AD brain and AD models have yielded conflicting results, related partly to differences in experimental models used, confounding effects on autophagy of expressing mutant proteins at high levels,[@cit0024] and tissue-level analyses often involving insufficient numbers of autophagy measures to confirm the functionality of a given step in the autophagic process.[@cit0062] Lipinski and coauthors[@cit0036] found in AD cortical tissue that transcription of genes promoting autophagy was generally upregulated and that of negative regulators was downregulated, consistent with our findings. Moreover, MTOR kinase activity is reduced in PSEN1/PS1-APP mouse brain and cells treated with Aβ1-42,[@cit0063] although it is reported to be increased in several other AD mouse models,[@cit0064] in inferior parietal lobule[@cit0035] in neurons exhibiting neurofibrillary degeneration in the AD brain,[@cit0066] and in cell models stimulated by Aβ oligomers[@cit0067] or mutant APP transfection.[@cit0064] In view of these controversial conclusions about the net direction of autophagy change in AD, we used a broad range of functional autophagy indices, involving molecular, biochemical, and imaging techniques and a focus on individual CA1 vulnerable neuron populations. The multidimensional approach in our study, which includes autophagy gene expression analysis, allowed us to conclude that autophagy is upregulated in AD brain.

Although autophagy gene expression is already upregulated at early AD stages, lysosomal degradative function becomes strikingly impaired beginning early (Br. III stage), but especially by the later Br. V stage as evidenced by buildup of SQSTM1/p62 and LC3-II, and the accumulation and increased colocalization of LC3 with CTSD within elevated numbers and area of enlarged autolysosomes. An MTORC1 downregulation due to impaired lysosomal proteolysis[@cit0016] may also be one cause for the observed activation and nuclear translocation of MiTF/TFE family transcription factors. Notably, the increased colocalization of LC3-II with CTSD in autolysosomes demonstrates that autophagosome-lysosome fusion is relatively preserved. Along the neurites of the most affected neurons, however, enlarged LC3-positive CTSD-negative autophagosomes were frequently seen although their presence is less likely a reflection of impaired AP-Ly fusion than to the fact that lysosomes are inefficiently transported into axons,[@cit0051] and their availability for fusion events may be limiting, especially when autophagosome formation is upregulated as in AD. Expansion of autolysosomal compartments, as seen in AD brain[@cit0068] is also seen upon inhibiting lysosomal proteolysis in vivo or in vitro,[@cit0051] and in mouse models of β-amyloidosis.[@cit0032] In the latter case, targeted enhancement of lysosomal proteolysis rescues deficits of synaptic plasticity, cognition, and substantially ameliorates amyloid deposition and tauopathy[@cit0032] underscoring the pathogenic importance of these lysosomal deficits. Moreover, when additional proteolytic dysfunction is superimposed on the brain in AD, such as that exerted by mutant PSEN1 (presenilin 1) on V-ATPase function and lysosomal acidification,[@cit0025] lysosomal pathology and disease onset are substantially accelerated. Such alterations of lysosomal pH, if present in AD brain, will negatively affect cathepsin maturation and activity,[@cit0073] explaining why CTSD upregulation alone would not be sufficient to maintain adequate clearance of lysosomal substrates.

Collectively, our findings suggest that in AD, early upregulation of autophagy is an initial neuroprotective response to cell stress,[@cit0074] which ultimately becomes counterproductive as lysosomal function becomes progressively impaired. Indeed, an increased substrate load in the presence of a developing AD-related impairment of lysosomal clearance,[@cit0069] serves as a 'double hit' on lysosomes. Failing lysosomes are further overburdened by an accelerated delivery of endocytic substrates driven by elevated levels of the APP β-C-terminal fragment in AD and mediated by an APP β-C-terminal fragment-APPL1-RAB5 mechanism.[@cit0075] Notably, endocytic pathway genes were the third most upregulated gene family in CA1 neurons of AD brain[@cit0038] and their upregulation early in disease[@cit0060] has been linked to abnormally accelerated endocytosis and accumulation of substrate in distal compartments in AD and DS.[@cit0046] The pathobiology in AD is reminiscent of Niemann-Pick Type C, a lysosomal storage disease sharing various neuropathological features with AD.[@cit0077] In Niemann-Pick Type C patient cells, primary lysosomal dysfunction is partially relieved by experimentally lowering an abnormally elevated level of autophagy induction.[@cit0078]

In conclusion, this multidimensional analysis of autophagy at different levels of the pathway in a specific vulnerable neuronal population highlights, for the first time, multiple alterations of autophagy in AD that provide new insight into the development of AV-laden dystrophic neurites that are a hallmark of AD neuropathology.[@cit0026] The novel observation that transcriptional factors regulating lysosomal biogenesis and function may be operating differentially in individual cell types in the brain is one of the various observations that underscore the importance of evaluating the autophagy pathway in single populations of cells in disease states, such as AD.

Materials and methods {#s0004}
=====================

Tissue {#s0004-0001}
------

For the custom-designed microarray analysis, tissue was procured from the Rush Religious Orders Study (RROS, Rush University Medical Center, Chicago, IL, USA) and the Center for Neurodegenerative Disease Research (CNDR, University of Pennsylvania, Philadelphia, PA, USA) as described previously by Ginsberg et al. with demographics shown in [Table 1](#t0001){ref-type="table"}.[@cit0038] Pathology as determined by the methodology of Braak and Braak was the primary criterion used to type tissues grouped as Controls (Br. 0-II, n = 10), Br. III/IV, n = 14, and Br. V/VI, n = 15).[@cit0079] Based on results from these analyses, subsequent studies were typed solely on the basis of the primary neuropathological assessment as described by Braak and Braak.[@cit0079] For qPCR and western blot analyses, fresh-frozen postmortem human brain tissue was obtained from the Harvard Brain Tissue Resource Center (HBTRC, McLean Hospital, Belmont, MA, USA) with demographic information outlined in [Table 3](#t0003){ref-type="table"}. For these studies, we used hippocampus from cases assigned an AD diagnosis at either Braak stage III (n = 10) or Braak stage V (n = 10) (see [Table 3](#t0003){ref-type="table"}). Nondemented, age-matched subjects with little or no AD pathology in these regions were analyzed as controls (Controls, n = 9). Groups were matched for age and postmortem interval ([Table 3](#t0003){ref-type="table"}). For single-cell analysis of transcriptional activators via qPCR, frozen samples of CA1 region were obtained from Emory University Alzheimer\'s Disease Research Center (ADRC), Atlanta, GA, USA with patient demographics shown in [Table 2](#t0002){ref-type="table"}. Finally, for ICC analysis of autophagic and lysosomal determinants and transcriptional activators, formalin-fixed hippocampi were procured from HBTRC and ADRC as shown in [Table 4](#t0004){ref-type="table"} and grouped as age-matched controls and Braak III or V as outlined above. Tissue was examined and neuropathological designations were based on NIA Reagan Recommendation, CERAD, and Braak staging criteria.[@cit0079] All studies were performed under the guidelines of the Institutional Review Board of the NYU Langone Medical Center and NKI. Clinical and neuropsychological evaluation criteria for the RROS/CNDR and ADRC cohorts have been published previously.[@cit0082] Antemortem cognitive assessment tests were performed, including the Mini-Mental State Exam (MMSE).[@cit0082] Scores were available within the last year of death. For the ADRC cohort used in single-cell qPCR analysis, patients were categorized as Control (n = 5) or moderate AD (n = 9) ([Table 2](#t0002){ref-type="table"}). Table 3.Demographics of Harvard Brain Tissue Resource Center (HBTRC) brain samples used in biochemical/molecular analyses.SampleCase numberBraak ScoreAgeGenderPMI (h)RINControl 1AN01404I74M18.36.2Control 2AN06429II77F23.35.1Control 3AN15823I76M24.24.4Control 4AN01717II79F20.64.2Control 5AN10180II73M24.05.6Control 6AN01234II85M20.85.4Control 7AN06221II82M24.15.3Control 8AN13219II93F12.36.7Control 9AN10936II86F23.86.5**Avg/Tot**  **80.6 + 6.55M/4F21.3 + 3.9** Br. III 1AN18315III81M23.86.0Br. III 2AN01765III88F14.94.2Br. III 3AN04145III94M15.66.2Br. III 4AN01725III84F13.25.1Br. III 5AN05918III85M6.15.0Br. III 6AN05919III85M6.15.0Br. III 7AN08520III89F17.84.5Br. III 8AN15998III82F18.86.7Br. III 9AN18315III82F17.45.1Br. III 10AN19132III84F8.64.4**Avg/Tot**  **85.4 + 3.94M/6F14.2 + 5.8** Br. V 1AN06801V76M23.75.3Br. V 2AN00391V89F15.02.5Br. V 3AN03479V83M26.65.3Br. V 4AN18658V80M20.63.8Br. V 5AN18751V76M12.56.9Br. V 6AN08533V84M12.65.2Br. V 7AN11070V86F15.36.3Br. V 8AN14636V89F15.85.4Br. V 9AN15437V90F20.55.2Br. V 10AN12565V76F21.45.9**Avg/Tot**  **83.2 + 5.65M/5F18.4 + 4.8** [^4] Table 4.Formalin-fixed hippocampal sections utilized in immunocytochemical analyses from Emory ADRC and Harvard HBTRC.Sample No.Case numberBrain bankBraak stagePMI (h)Age at onsetAge at deathDurationApoERace/SexCtr. 1E08-101ADRCII17 78 E3/3WFCtr. 26865HBTRCND18.7 78  FCtr. 36573HBTRCND15 79  FCtr. 47862HBTRCND18.0 73  MCtr. 58341HBTRCND15.7 82  FCtr. 65326HBTRCND12.1 75  FCtr. 75859HBTRC012.5 60  FCtr. 85919HBTRCII18.7 80  MCtr. 95452HBTRCND7.6 73  MCtr. 105832HBTRCI16.7 75  FCtr. 115619HBTRCND      Ctr. 125582HBTRCND  74   **AVG/Total**   **15.2 + 3.5** **75.2 + 5.8**  **7F/3M**Br. III 1OS03-76ADRCIII17.570788E3/3WMBr. III 2E08-127ADRCIII2076826E4/4BFBr. III 3E10-30ADRCIII2779013E3/3WFBr. III 46776HBTRCIII17.2 80  F**AVG/Total**   **14.2 + 8.2** **82.5 + 5.3**  **3F/1M**Br. V 1E08-97ADRCV19 78 E3/4WFBr. V 2E06-15ADRCV13.567725E3/4WMBr. V 35979HBTRCVI17.9 80  MBr. V 45035HBTRCV20 75  FBr. V 56209HBTRCV13 75  FBr. V 66917HBTRCV24.1 79  FBr. V 76297HBTRCV6.5 75  FBr. V 86265HBTRCV7.9 78  FBr. V 96215HBTRCV15 82  MBr. V 106164HBTRCV14.1 73  MBr. V 115850HBTRCV5 73  M**AVG/Total**   **14.2 + 6.0** **76.4 + 3.4**  **6F/5M**[^5] Table 5.Primers used for qPCR analyses.FunctionGene nameProtein nameProbe I.D.Housekeeping*ACTB*actin βHs99999903_m1 *GAPDH*glyceraldehyde-3-phosphate dehydrogenaseHs00266705_g1 *HPRT1*hypoxanthine phosphoribosyltransferase 1Hs00266705_g1 *SDHA*succinate dehydrogenase complex flavoprotein subunit AHs00417200_m1Transcriptional activator*TFEB*transcription factor EBHs01065086_m1 *TFE3*transcription factor binding to IGHM enhancer 3Hs00232406_m1 *FOXO1*forkhead box O1Hs01054576_m1 *FOXO3*forkhead box O3Hs00818121_m1Autophagosome formation-elongation*ULK1*unc-51 like autophagy activating kinase 1Hs00177504_m1 *ATG5*autophagy related 5Hs00169468_m1 *ATG12*autophagy related 12Hs01047860_g1 *ATG7*autophagy related 7Hs00894898_m1 *MAP1LC3B/LC3B*microtubule associated protein 1 light chain 3 βHs00917683_m1 *BECN1*beclin 1Hs00186838_m1 *PIK3C3/VPS34*phosphatidylinositol 3-kinase catalytic subunit type 3Hs00176908_m1 *SQSTM1/p62*sequestosome 1Hs00177654_m1Lysosome*CTSD*cathepsin DHs00157205_m1 *CTSB*cathepsin BHs00947433_m1 *LAMP1*lysosomal associated membrane protein 1Hs00174766_m1 *LAMP2*lysosomal associated membrane protein 2Hs00174474_m1[^6]

ICC {#s0004-0002}
---

Formalin-fixed, human hippocampus ([Table 4](#t0004){ref-type="table"}) was sectioned at 40 μm on a vibratome (Leica Biosystems, Buffalo Grove, IL, USA) for LC3 (MBL Int., M152-3; mouse monoclonal) and CTSD (Scripps Laboratories, RC245; rabbit polyclonal) colocalization, or paraffin embedded and sectioned at 7 μm for TFE3 and TFEB (Cell Signaling Technology, 14779 and 4240, respectively; polyclonal rabbit) immunolabeling. Where applicable, paraffin sections were deparaffinized. Antigen-retrieval was performed by heating tissue sections in sodium citrate buffer (10 mM, pH 6.0) at 95°C for 20 min. Sections were blocked and incubated in primary antibody in 1xTris-buffered saline (50 mM Tris-HCl, pH 7.4, 150 mM NaCl) containing 0.1% Tween-20 (v:v; Fisher Scientific, BP337) and 3% normal goat serum (v:v; Vector Laboratories, S-1000) for up to 3 days at 4°C. Alexa Fluor-conjugated secondary antibodies (ThermoFisher/Life Technologies, A-11029, A-11010, A-11008, A-11003) were used for immunofluorescence and ABC detection was used for DAB (Vector Laboratories, PK-4005). Autofluorescence was quenched with 1-2.5 mM CuSO~4~ in 50 mM ammonium acetate, pH 5.0 for 60 min at RT. For CTSD/LC3 stained imaging, sections were stained in 600 nM DAPI (Sigma, D9542) for 15 min at room temperature prior to mounting. DAB labeling of TFE3 following cresyl violet staining for 15 min was inspected on a Zeiss AxioSkop II equipped with an HrM digital camera (Zeiss USA, Thornwood, NY, USA). Sections labeled for TFEB were counterstained for Nissl using cresyl violet as described by Alvarez-Buylla.[@cit0086] In CA1, glia were differentiated from pyramidal neurons on the basis of morphology and nuclear staining by DAPI or cresyl violet Nissl staining.[@cit0086] Immunofluorescent images for CSTD, LC3, or TFEB were collected on a confocal microscope (Zeiss LSM510 or LSM810). Pearson\'s correlation coefficient was quantified using ZEN V. 2.1 software from Zeiss. Quantifications for LC3- and CTSD-immunoreactive puncta were performed using FIJI software.[@cit0087] Fluorescence images were adjusted for brightness, contrast and color balance by using Adobe Photoshop CS (San Jose, CA, USA).

Single population microarray {#s0004-0003}
----------------------------

Immunocytochemistry to identify neurofilament-immunoreactive CA1 neurons for laser capture microdissection[@cit0088] and terminal continuation (TC) RNA amplification procedures have been described in detail previously.[@cit0038] Individual CA1 pyramidal neurons from fresh-frozen hippocampi ([Table 1](#t0001){ref-type="table"}) were microaspirated via LCM (Arcturus PixCell IIe, MDS, Sunnyvale, California). Fifty cells were captured for population cell analysis. A total of 212 custom-designed arrays were performed on the cohort of subjects as described previously.[@cit0038] The TC RNA amplification procedure has been employed previously using human CA1 pyramidal neurons accessed via LCM as input sources of RNA.[@cit0038] The TC RNA amplification protocol is available at <http://cdr.rfmh.org/pages/ginsberglabpage.html>. Array platforms consisted of 1 μg of linearized cDNA purified from plasmid preparations adhered to high-density nitrocellulose (GE Healthcare, Hybond XL). 578 cDNAs/ESTs were utilized on the current array platform. All of the autophagic and endosomal-lysosomal genes were derived from human sequences. Procedures for custom-designed microarray analysis and patients\' demographics have been described in detail.[@cit0038] Microarray analysis was performed on CA1 pyramidal neurons obtained from Controls (Br. 0-II, n = 10), Br. III/IV (n = 14), and Br. V/VI (n = 15) cases ([Table 1](#t0001){ref-type="table"}). Briefly, expression of TC-amplified RNA bound to each linearized cDNA minus background was expressed as a ratio of the total hybridization signal intensity of the array, enabling a profile of relative changes in mRNA levels. Relative changes in total hybridization signal intensity were analyzed by mixed models analysis for repeated measures, with random intercept, fixed effect for diagnosis, Kenward-Roger denominator degrees of freedom, and unequal variance assumption as warranted.[@cit0038] The level of statistical significance was set at (p \< 0.01); trend level changes were characterized as (p \< 0.02) -- (p \< 0.05) as described previously.[@cit0090]

RNA preparation {#s0004-0004}
---------------

For routine qPCR analyses 100 mg of gray matter from hippocampus procured from the Harvard Brain Tissue Resource Center (HBTRC), part of the NeuroBioBank organism ([Table 3](#t0003){ref-type="table"}), was dissected and extracted in 1.5 ml Trizol reagent (ThermoFisher/Life Technologies, 15596026) using a hand-held homogenizer (6 × 15 s bursts; Pro-Scientific, Oxford, CT, USA) followed by mixing with 300 μL of chloroform. Samples were centrifuged at 12000 g for 15 min at 4°C. The aqueous phase was collected and 750 μL isopropanol was added; samples were spun again at 12000 g for 10 min at 4°C. Supernatant was removed and the pellet washed 2 times with 75% ice-cold ethanol and centrifuged at 7500 g for 5 min at 4°C. The pellet was redissolved in 100 μL of RNAase-free distilled water. Total RNA quality (RNA Integrity Number) was assessed on an Agilent Bioanalyzer using an RNA Nanochip (2100; Agilent Technologies; Santa Clara, CA).

For analysis of transcriptional activators, slides were prepared from 40-μm sections cut from fresh-frozen samples of CA1 region obtained from Emory University Alzheimer\'s Disease Research Center (see [Table 2](#t0002){ref-type="table"}) in a cryotome (MICROM, Walldorf, Germany). Slides were placed on a precooled metal plate and regions enriched in CA1 pyramidal neurons were visualized under a dissecting microscope using the Human Brain Atlas to reconnoiter landmarks. Cells were scraped using an ice-cold scalpel and collected in microcentrifuge tubes. Cells were extracted for total RNA using the TaqMan Gene Expression Cells-To-C~T~ kit (ThermoFisher/Life Technologies, 439902) as per the manufacturer\'s instructions with the following modifications: Cells were lysed in 50 μl Lysis Buffer containing DNAse1 to remove contaminating genomic DNA for 5 min at room temperature, followed by the addition of 5 μl Stop solution for 2 min. Two reactions per sample were pooled and 22.5 μl subjected to reverse transcription in a final volume of 40 μl. Following reverse transcription, aliquots of 10 μl in triplicate were used for qPCR analysis as described below.

Preparation of cDNA and qPCR {#s0004-0005}
----------------------------

cDNA was prepared from total RNA using TaqMan Reverse Transciption Reagent kit (ThermoFisher/Life Technologies, N808-0234) according to the manufacturer\'s instructions. Following reverse transcription, 20 ng of sample cDNA was loaded in triplicate into wells of a 96-well optical reaction plate (ThermoScientific, AB-2100) containing appropriate target gene primer ([Table 5](#t0005){ref-type="table"}; ThermoFisher/Life Technologies). Three housekeeping genes were run and assessed for stability: *GAPDH* (glyceraldehyde 3-phosphate dehydrogenase), *ACTB* (actin β), and *HPRT1* (hypoxanthine phosphoribosyltransferase 1). Total reaction volume per well was 20 μL. In the case of single cell transcriptional activators, the housekeeping genes used were *GAPDH* and *SDHA* (succinate dehydrogenase complex flavoprotein subunit A) and total reaction volume was 10 μl. qPCR was performed in the ABI Prism 7900HT Sequence Detection System (Applied Biosystems Branchburg, NJ, USA) as described previously.[@cit0091]

Gene Ontology (GO) analysis {#s0004-0006}
---------------------------

The GO analysis was done using the Database for Annotation, Visualization and Integrated Discovery (DAVID) v6.7 as described previously.[@cit0055] A unique list of gene symbols was uploaded including all significantly upregulated genes in MCI and AD compared to control, detected by the single population microarray.

Calculation of qPCR results {#s0004-0007}
---------------------------

Following qPCR, the target genes were normalized against the housekeeping genes. Results were calculated using the ΔΔCt method (Applied Biosystems, Branchburg, NJ, USA, Bulletin \#2). Control values were averaged as a geometric mean and sample values were recalculated and expressed as percent control.[@cit0093] Outliers were recognized as values falling beyond 2 standard deviations of the mean, and were discarded from the analyses.

Preparation of tissue extracts {#s0004-0008}
------------------------------

100 mg of brain tissue procured from HBTRC corresponding to samples used for qPCR ([Table 3](#t0003){ref-type="table"}) was homogenized as previously described[@cit0095] in a Tissue Homogenization buffer (50 mM Tris-HCl, pH 8.0, 150 mM NaCl, 1 mM each EDTA, EGTA and DTT, 250 mM sucrose (EMD Millipore, SX1075, 1 mM β-glycerophosphate, 1 mM NaF, 0.2 mM NaVO~4,~ 5 μg/ml each leupeptin (Sigma, L5793, antipain (Sigma, A6191) and pepstatin (Enzo Life Sciences, 260-009) and 1 mM each benzamidine (Sigma, 434760) and PMSF (Sigma, P7626)). For enzymatic activity assays, extracts were acidified with 0.4 M NaAc, pH 5 and supernatants used as described previously.[@cit0031] Protein content was determined by the BCA method.[@cit0096] The lysates were solubilized in Laemmli buffer for western blotting.

SDS-PAGE and western blotting {#s0004-0009}
-----------------------------

SDS-polyacrylamide gel electrophoresis followed by western blotting was performed as described previously.[@cit0097] The immunoreactive bands were visualized with ECL reagent (Amersham, RPN2209) and the bands were quantified using MultiGauge V. 3.0 (Fuji Film) software. Target proteins were normalized against ACTB/β-actin, unless otherwise noted.

Antibodies for western analyses {#s0004-0010}
-------------------------------

TUBB3 (Clone TU-20; Sigma, SAB4700544), GFAP (Sigma, SAB4501162), TFE3 (Sigma, HPA023881), ATG7 (Cell Signaling Technology, 2631), TFEB (Cell Signaling Technology, 4240), FOXO1 (Cell Signaling Technology, 2880), FOXO3 (Cell Signaling Technology, 2497) ULK1 (Cell Signaling Technology, 4773), BECN1 (BD Biosciences, 612113), SQSTM1/p62 (BD Biosciences, 610832), LC3 (Novus Biologics, NB100-2220), LAMP1 and LAMP2 (Developmental Studies Hybridoma Bank, University of Iowa, H4A3 and H4B4, respectively), CTSD D-2-3,[@cit0098] CTSB (Cortex Biochemicals, CR6009RP) and TFEB (Bethyl Laboratories, A303-672 and -673).

Statistical analysis of qPCR and western blot analyses {#s0004-0011}
------------------------------------------------------

Statistical significance was tested using one-way analysis of variance (ANOVA) with post-hoc analysis of Dunnett\'s Comparison to Control test, assessed with Graphpad Prism software, V. 6.0. If the ANOVA was found significant (\*p ≤ 0.05), then the Family-Wise Error Rate is protected at 0.05 using Student *t* test as reported in the text or shown in Figures. Alternatively, if the ANOVA is not significant, it is necessary to use the Dunnett\'s Multiple Comparison Test of the Family-Wise Error Rate at 0.05 as reported in the text or shown in Figures. For size distribution analyses, significance was determined by 2-way ANOVA assessed with Graphpad Prism software.
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[^1]: Color versions of one or more of the figures in the article can be found online at [www.tandfonline.com/kaup](http://www.tandfonline.com/kaup).

[^2]: Abbreviations: W, white; B, black, ND, not divulged; PMI, Postmortem interval.

[^3]: Abbreviations: W, white; B, black; PMI, Postmortem interval.

[^4]: Abbreviations: RIN, RNA Integrity Number; PMI, Postmortem interval.

[^5]: Abbreviations: ND, not divulged; B, black; W, white; PMI, postmortem interval.

[^6]: Taq-Man validated primers purchased from Life Technologies/ThermoFisher.
